. Correction to Lyden P, Pryor KE, Coffey CS, et al. Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated Ann Neurol 2023 Dec 21. doi: 10.1002/ana.26841.
PMID: 38126938